Kalaris Therapeutics Files 8-K on Shareholder Nominations
Ticker: KLRS · Form: 8-K · Filed: Jun 20, 2025 · CIK: 1754068
| Field | Detail |
|---|---|
| Company | Kalaris Therapeutics, Inc. (KLRS) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, shareholder-nomination, corporate-action
TL;DR
Kalaris Therapeutics filed an 8-K for shareholder nominations - board changes incoming?
AI Summary
Kalaris Therapeutics, Inc. filed an 8-K on June 20, 2025, reporting an event on June 19, 2025, related to shareholder nominations under Exchange Act Rule 14a-11 and other events. The company, formerly known as Allovir, Inc. and ViraCyte, Inc., is incorporated in Delaware and based in Palo Alto, California.
Why It Matters
This filing indicates potential changes or discussions regarding the company's board of directors or governance structure, which could impact strategic direction.
Risk Assessment
Risk Level: medium — Filings related to shareholder nominations and board composition can signal internal disputes or strategic shifts that may affect stock performance.
Key Players & Entities
- Kalaris Therapeutics, Inc. (company) — Registrant
- Allovir, Inc. (company) — Former company name
- ViraCyte, Inc. (company) — Former company name
- June 19, 2025 (date) — Earliest event date
- June 20, 2025 (date) — Report date
- Exchange Act Rule 14a-11 (regulation) — Subject of shareholder nominations
FAQ
What specific 'Other Events' are being reported by Kalaris Therapeutics in this 8-K filing?
The provided text of the 8-K filing does not detail the specific 'Other Events', only that they are being reported.
What is the significance of 'Shareholder Nominations Pursuant to Exchange Act Rule 14a-11' for Kalaris Therapeutics?
This indicates that shareholders may be nominating individuals for the company's board of directors, potentially leading to changes in governance or strategy.
When was Kalaris Therapeutics previously known as Allovir, Inc. and ViraCyte, Inc.?
The company was formerly known as Allovir, Inc. after changing its name from ViraCyte, Inc. on May 21, 2019, and ViraCyte, Inc. prior to September 24, 2018.
What is the principal business address and phone number for Kalaris Therapeutics?
The principal executive offices are located at 628 Middlefield Road, Palo Alto, California 94301, and the telephone number is (650) 249-2727.
What is the SIC code for Kalaris Therapeutics and what industry does it represent?
The Standard Industrial Classification (SIC) code is 2836, which represents 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 20, 2025 regarding Kalaris Therapeutics, Inc. (KLRS).